Vor Biopharma (NASDAQ:VOR) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research note published on Thursday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $30.00 target price on the stock.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. JPMorgan Chase & Co. decreased their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. TD Cowen started coverage on shares of Vor Biopharma in a research note on Wednesday, December 17th. They issued a “buy” rating for the company. Wedbush initiated coverage on shares of Vor Biopharma in a research report on Tuesday, November 25th. They set a “neutral” rating on the stock. Finally, Citigroup began coverage on shares of Vor Biopharma in a research note on Friday, January 9th. They set a “buy” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.88.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $12.04 on Thursday. Vor Biopharma has a 1-year low of $2.62 and a 1-year high of $65.80. The business has a fifty day moving average price of $14.33 and a 200-day moving average price of $19.05. The stock has a market capitalization of $125.34 million, a price-to-earnings ratio of -0.03 and a beta of 1.99.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the fourth quarter worth about $229,000. Susquehanna Portfolio Strategies LLC acquired a new position in Vor Biopharma in the 4th quarter worth approximately $134,000. Tudor Investment Corp ET AL purchased a new position in Vor Biopharma during the 4th quarter worth approximately $2,193,000. Sphera Funds Management LTD. purchased a new position in Vor Biopharma during the 4th quarter worth approximately $5,368,000. Finally, Quadrature Capital Ltd acquired a new stake in Vor Biopharma during the 4th quarter valued at approximately $350,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).